Phase 1/2 Trial of LY3884961 for Gaucher Disease Initiated by Prevail Therapeutics
Prevail Therapeutics has launched Phase 1/2 clinical trial for LY3884961 in patients with peripheral manifestations of Gaucher Disease.
Phase I
Gaucher Disease therapies
Status
Initiated
Sponsor
Prevail Therapeutics
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of the Phase 1/2 trial for LY3884961 by Prevail Therapeutics represents a significant development in the treatment landscape for Gaucher Disease. This could shift competitive dynamics and influence investment strategies in genetic disorder therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor patient enrollment progress and initial safety and efficacy data over the next 18 months.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.